// App-Quantinova.ai

5010 : Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)A University of Chicago phase II consortium trial.

Researchers

Presenter

  • Maha Hussain

Principal Investigators

  • Przemyslaw Twardowski

  • Costantine Albany

  • Mark N. Stein

  • Lakshmi Priya Kunju

  • Javed Siddiqui

  • Dan Robinson

  • Rohit Mehra

  • Kathleen A. Cooney

  • Robert B. Montgomery

  • Emmanuel S. Antonarakis

  • Daniel H. Shevrin

  • Paul Gettys Corn

  • Young E. Whang

  • David C. Smith

  • Megan Veresh Caram

  • Walter Michael Stadler

  • Felix Yi-Chung Feng

  • Arul M. Chinnaiyan

Medical Centers

  • University of Michigan, Ann Arbor, MI

  • Department of Biostatistics, University of Michigan, Ann Arbor, MI

  • City of Hope, Duarte, CA

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Center for Translational Pathology, University of Michigan, Ann Arbor, MI

  • University of Washington, Seattle, WA

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • NorthShore University HealthSystem, Evanston, IL

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of North Carolina, Chapel Hill, NC

  • The University of Chicago Medical Center, Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Blood/haematological Diseases

Disease

  • Metastatic castration-resistant prostate cancer

  • Fanconi anemia, complementation group A

Biomarkers

  • Poly(ADP-Ribose) Polymerase 1

  • Prostate specific antigen

  • Fanconi anaemia, complementation group A

  • BRCA mutation

  • Partner and localizer of BRCA2

  • RAD51 Paralog C

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • CB-7598

  • Prednisone

  • Veliparib

  • Androgen Tear

Outcome

  • Positive

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01576172

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved